Table 2.
Patients’ characteristics
| Case | Sex | Age | Etiology | Child-Pugh score (Points) | Stage1 | BCLC2 | Maintenance dose (mg/kg per day) | Administration period (d) | Response |
AFP (ng/mL) |
DCP (mAU/mL) |
||
| Baseline | After 1 course | Baseline | After 1 course | ||||||||||
| 1 | M | 80 | HCV | B (7) | IVA | C | 10 | 17 | PD | 1918 | - | 57 | - |
| 2 | M | 73 | HBV | B (7) | III | C | 10 | 35 | PD | 127402 | 260627 | 73 | 61 |
| 3 | M | 72 | HBV | B (8) | III | B | 5 | 248 | SD | 189 | 394 | 85 | 25 |
| 4 | M | 65 | HBV | A (5) | IVA | C | 10 | 28 | PD | 603 | 814 | 9995 | 16793 |
| 5 | F | 70 | HCV | A (6) | IVA | C | 15 | 29 | PD | 5580 | 8434 | 19958 | 15321 |
| 6 | F | 60 | HCV | A (6) | IVA | C | 15 | 28 | PD | 6172 | 7671 | 4606 | 2283 |
1
According to Liver Cancer Study Group of Japan;
2
According to Barcelona Clinic Liver Cancer. HCV: Hepatitis C virus; HBV: Hepatitis B virus; AFP: Alfha-fetoprotein; DCP: Des-gamma-carboxy prothrombin. PD: Progressive disease; SD: Stable disease.